Foxo4-Dri
Peptide therapy: benefits, side effects, cost and protocols
FOXO4-DRI is a cell-penetrating peptide designed to selectively induce apoptosis in senescent cells (senolytic therapy). It works by disrupting the interaction between FOXO4 and p53, causing senescent cells to undergo programmed cell death while leaving healthy cells unaffected.
Sources: FDA / PubMed / ClinicalTrials.gov View
Spec sheet
- FDA status
- Research Only Not currently approved for human use in the US. Available as a research compound. Not eligible for compounding.
- Evidence
- Anecdotal
Mechanism
How Foxo4-Dri works
Disrupts FOXO4-p53 interaction in senescent cells, potentially triggering apoptosis specifically in these aged, dysfunctional cells.
FAQ
Foxo4-Dri questions
What is FOXO4-DRI?
FOXO4-DRI is a research peptide designed to selectively target and clear senescent cells, which accumulate with age and contribute to aging processes.
How does FOXO4-DRI work?
Disrupts FOXO4-p53 interaction in senescent cells, potentially triggering apoptosis specifically in these aged, dysfunctional cells.
Is FOXO4-DRI legal to buy?
FOXO4-DRI is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.
Where can I buy FOXO4-DRI?
FOXO4-DRI is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.
What category does FOXO4-DRI belong to?
FOXO4-DRI is primarily classified as a anti-aging & longevity peptide. Peptides studied for longevity, cellular senescence, telomere biology, and general anti-aging effects.
What are the research benefits of FOXO4-DRI?
FOXO4-DRI has been studied for: Senescent cell clearance, Anti-aging research, Cellular renewal. Senescence clearance; experimental anti-aging research.
News
Foxo4-Dri in the news
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation - Nature
Nature / 19 months ago
Molecule kills elderly cells, reduces signs of aging in mice - Science | AAAS
Science | AAAS / 116 months ago
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI - Nature
Nature / 15 months ago
Bioinformatics procedure for investigating senolytic (anti-aging) agents: A digital signal processing technique - Wiley Online Library
Wiley Online Library / 33 months ago
The mouse that time forgot - de Volkskrant
de Volkskrant / 103 months ago
News aggregated via Google News. Inclusion does not imply endorsement.
Related
Other Anti-Aging & Longevity peptides
Full peptide index →Considering Foxo4-Dri?
The 2-minute quiz matches you with licensed providers who offer it. A clinician decides if it fits.